Fragile X Syndrome (FXS) Market

Jul 14, 2020

10 likes | 62 Views

The total cases of Fragile X Syndrome (FXS) in the 7MM was 117,962 in 2017. While in the United States, the diagnosed prevalent cases of FXS in 2017 was found to be 67,654. The market size of Fragile X Syndrome (FXS) was USD 33.8 Million in 2017 and is expected to increase during the forecast period 2017-2030. Some of the key factors which may drive the FXS market forward in the coming years includes: Development of novel therapies. Identifying potential targets by animal models. Funding and cooperation of various organizations. And many others. The key pharma companies in the Fragile X Syndrome (FXS) market include Zynerba Pharmaceuticals, Tetra Therapeutics, Confluence Pharmaceuticals, Neuren Pharmaceuticals, Ovid Therapeutics, Marinus Pharmaceuticals, Alcobra Pharmaceuticals/ Arcturus Therapeutics and many others. For more detailed information on Fragile X Syndrome (FXS) market, visit: https://www.delveinsight.com/report-store/fragile-x-syndrome-fxs-market #geneticdisorder #FragileXsyndrome #FXS #mentalretardation #inheriteddisorder

DelveInsight

Download Presentation

Fragile X Syndrome (FXS) Market

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D